首页> 美国卫生研究院文献>HPB Surgery >Preoperative Gadoxetic Acid-Enhanced MRI and Simultaneous Treatment of Early Hepatocellular Carcinoma Prolonged Recurrence-Free Survival of Progressed Hepatocellular Carcinoma Patients after Hepatic Resection
【2h】

Preoperative Gadoxetic Acid-Enhanced MRI and Simultaneous Treatment of Early Hepatocellular Carcinoma Prolonged Recurrence-Free Survival of Progressed Hepatocellular Carcinoma Patients after Hepatic Resection

机译:术前放牛酸增强MRI和同时治疗早期肝细胞癌进展期肝细胞癌患者肝切除术后无复发生存时间延长

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background/Purpose. The purpose of this study was to clarify whether preoperative gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) and simultaneous treatment of suspected early hepatocellular carcinoma (eHCC) at the time of resection for progressed HCC affected patient prognosis following hepatic resection. Methods. A total of 147 consecutive patients who underwent their first curative hepatic resection for progressed HCC were enrolled. Of these, 77 patients underwent EOB-MRI (EOB-MRI (+)) before hepatic resection and the remaining 70 patients did not (EOB-MRI (−)). Suspected eHCCs detected by preoperative imaging were resected or ablated at the time of resection for progressed HCC. Results. The number of patients who underwent treatment for eHCCs was significantly higher in the EOB-MRI (+) than in the EOB-MRI (−) (17 versus 6; P = 0.04). Recurrence-free survival (1-, 3-, and 5-year; 81.4, 62.6, 48.7% versus 82.1, 41.5, 25.5%, resp., P < 0.01), but not overall survival (1-, 3-, and 5-year; 98.7, 90.7, 80.8% versus 97.0, 86.3, 72.4%, resp., P = 0.38), was significantly better in the EOB-MRI (+). Univariate and multivariate analyses showed that preoperative EOB-MRI was one of the independent factors significantly correlated with better recurrence-free survival. Conclusions. Preoperative EOB-MRI and simultaneous treatment of eHCC prolonged recurrence-free survival after hepatic resection.
机译:背景/目的。这项研究的目的是弄清术前加达西酸增强磁共振成像(EOB-MRI)和在切除时同时进行疑似早期肝细胞癌(eHCC)的同时治疗是否进展为肝癌,会影响肝切除术后的患者预后。方法。总共纳入了147例因肝癌进展而进行首次根治性肝切除的患者。其中,有77例患者在肝切除之前接受了EOB-MRI(EOB-MRI(+))治疗,其余70例没有进行(EOB-MRI(-))。术前影像学检查发现可疑的eHCC在切除时会因进展的HCC而切除或消融。结果。在EOB-MRI(+)中接受eHCC治疗的患者数量明显高于EOB-MRI(-)(17比6; P = 0.04)。无复发生存期(1年,3年和5年; 81.4%,62.6%,48.7%与82.1%,41.5%,25.5%,相对,P <0.01),但无总生存期(1、3和3年) 5年; 98.7、90.7、80.8%与97.0、86.3、72.4%(分别为P = 0.38)相比,在EOB-MRI中显着更好(+)。单因素和多因素分析表明,术前EOB-MRI是与更好的无复发生存率显着相关的独立因素之一。结论。术前EOB-MRI和同时治疗eHCC可延长肝切除术后的无复发生存期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号